VITREORETINAL TECHNOLOGIES
Vitreoretinal Technologies, Inc., an ophthalmic biopharmaceutical company, engages in the development and commercialization of therapeutic compounds for the treatment of ophthalmic diseases. The company focuses on vitreoretinal ophthalmic diseases and complications related to ophthalmic surgery. Its products include Vitreosolve, a drug used for the treatment of diabetic retinopathy, as well as to liquefy the vitreous gel prior to vitrectomy surgery; and Neurosolve, a compound used for glaucomatous optic nerve damage progression prevention, dry age related macular degeneration progression, and retinitis pigmentosa treatment.
VITREORETINAL TECHNOLOGIES
Industry:
Biotechnology Health Care Therapeutics
Founded:
1999-01-01
Address:
Irvine, California, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
12 M USD
Similar Organizations
Anthos Therapeutics
Anthos Therapeutics is a biopharmaceutical company that specializes in the treatment of cardiovascular and metabolic diseases.
Genelabs Technologies
Genelabs Technologies is a biopharmaceutical company engaged in the R&D of therapeutics for the treatment of infectious diseases.
Investors List
DeNovo Ventures
DeNovo Ventures investment in Series A - Vitreoretinal Technologies